Interventional, Randomised, Double-blind, Placebo Controlled, Multiple-dose Study Investigating the Safety, Tolerability, PK and PD Properties of Lu AF11167 in Patients With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2015
At a glance
- Drugs Lu AF11167 (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 17 Feb 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jan 2015, according to the ClinicalTrials.gov record.